Table 2.
Current clinical trials of combination therapies to overcome the BRAF inhibitors resistance in patients with melanoma
| TrialID | Public title | Year | Recruitment Status | Phase | Intervention | Drug target |
|---|---|---|---|---|---|---|
| NCT04903119 | Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma | 2021 | Recruiting | 1 | Trametinib, Dabrafenib, Nilotinib | MEK, BRAF, KIT, PDGFR |
| NCT04557956 | Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment | 2020 | Recruiting | 1/2 | Trametinib, Dabrafenib, Tazemetostat | MEK, BRAF, EZH2 |
| NCT04527549 | Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma | 2020 | Recruiting | 2 | Trametinib, Dabrafenib, Hydroxychloroquine | MEK, BRAF, Autophagy |
| NCT04375527 | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma | 2020 | Recruiting | 2 | Binimetinib, Nivolumab | MEK, PD-1 |
| NCT03972046 | Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma | 2019 | Active, not recruiting | 2 | Trametinib, Dabrafenib, Talimogene laherparepvec (T-Vec) | MEK, BRAF, GM-CSF |
| NCT04201457 | A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration | 2019 | Recruiting | 1/2 | Trametinib, Dabrafenib, Hydroxychloroquine | MEK, BRAF, Autophagy |
| NCT03580382 | Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma | 2018 | Active, not recruiting | 1/2 | Trametinib, CDX-3379 | MEK, ERBB3 |
| NCT03543969 | Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | 2018 | Recruiting | 1 | Cobimetinib, Vemurafenib | MEK, BRAF |
| NCT03455764 | MCS110 With BRAF/MEK Inhibition in Patients With Melanoma | 2018 | Active, not recruiting | 1/2 | Trametinib, Dabrafenib, MCS110 | MEK, BRAF, CSF-1 |
| NCT03668431 | Dabrafenib + Trametinib + PDR001 In Colorectal Cancer | 2018 | Recruiting | 2 | Trametinib, Dabrafenib, PDR001 | MEK, BRAF, PD-1 |
| NCT03693170 | Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer ANCHOR-CRC | 2018 | Active, not recruiting | 2 | Binimetinib, encorafenib, Cetuximab | MEK, BRAF, EGFR |
| NCT03101254 | LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma | 2017 | Active, not recruiting | 1/2 | Cobimetinib, Vemurafenib, LY3022855 | MEK, BRAF, CSF-1 |
| NCT03026517 | Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma | 2017 | Recruiting | 1 | Trametinib, Dabrafenib, Phenformin | MEK, BRAF, Activation of AMPK |
| NCT03272464 | INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAFmutant Melanoma and Other Solid Tumors. | 2017 | Active, not recruiting | 1 | Trametinib, Dabrafenib, INCB039110 | MEK, BRAF, JAK1 |
| NCT02967692 | A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma | 2016 | Active, not recruiting | 3 | Trametinib, Dabrafenib, Spartalizumab | MEK, BRAF, PD-1 |
| NCT02858921 | Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma Neo Trio | 2016 | Active, not recruiting | 2 | Trametinib, Dabrafenib, Pembrolizumab | MEK, BRAF, PD-1 |
| NCT02382549 | A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | 2015 | Recruiting | 1 | Trametinib, Dabrafenib, 6MHP | MEK, BRAF, Induce T cell and Ab responses |